-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mycophenolate mofetil is the main treatment for rheumatism and musculoskeletal diseases ( RMD ) for many organs and vital signs
.
Compared with most patients with RMD, patients taking mycophenolate mofetil had a weakened humoral response to SARS-CoV-2 mRNA vaccine
Mycophenolate mofetil is the main treatment for rheumatism and musculoskeletal diseases ( RMD ) for many organs and vital signs
Logistic regression is used to evaluate the association between antibody response and mycophenolate mofetil, and the logistic regression analysis is adjusted to adjust for age, gender, race, vaccine type ( mRNA VS adenovirus vector), use of rituximab and glucocorticoids.
Features
After vaccination with a median of 32 ( 28-35 ) days, the antibody response was detectable in patients who discontinued mycophenolate mofetil on 22/24 , which was significantly higher than that of patients who continued to use mycophenolate mofetil ( 112/171 ) ( 92% vs 65%, p=0.
in conclusion:
Conclusion: Conclusion:Preliminary results show that it is safe to stop mycophenolate mofetil before and after SARS-CoV-2 vaccination in patients with rheumatism and musculoskeletal diseases , and can enhance antibody response .
Preliminary results show that it is safe to stop mycophenolate mofetil before and after SARS-CoV-2 vaccination in patients with rheumatism and musculoskeletal diseases , and can enhance antibody response .Source: Source:
Connolly CM, Chiang TP, Boyarsky BJ, Ruddy JA, Teles M, Alejo JL, Massie A, Werbel WA, Shah AA, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ.
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
Connolly CM, Chiang TP, Boyarsky BJ, Ruddy JA, Teles M, Alejo JL, Massie A, Werbel WA, Shah AA, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ.
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
Ann Rheum Dis.
2021 Sep 23:annrheumdis-2021-221252.
doi: 10.
1136/annrheumdis-2021-221252.
Epub ahead of print.
PMID: 34556484.
Leave a message here
